The decision by London boroughs to provide more than 4,000 extra places on the NHS-led PrEP Impact Trial is a major boost to HIV prevention in the capital.
There is extensive evidence that HIV transmissions are reduced when PrEP – an HIV prevention medicine – is used by people at high risk of exposure. This is why promoting PrEP is an integral part of the boroughs’ collaborative London HIV Prevention Programme, which has overseen sizeable reductions in new HIV diagnoses in recent years.
Want full article access?
Receive The MJ magazine each week and gain access to all the content on this website with a subscription.
Full website content includes additional, exclusive commentary and analysis on the issues affecting local government.
Already a subscriber? Login